We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
167 result(s) found, displaying 51 to 60
-
Prescription medicine registrationActive ingredients: concizumab.
-
Prescription medicine decision summaryTGA decision: Esperoct (turoctocog alfa pegol) is approved to treat haemophilia A.
-
Prescription medicine registrationActive ingredients: turoctocog alfa pegol.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SOGROYA somapacitan 10 mg (6.7 mg/mL) solution for injection prefilled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBELSUS semaglutide 14 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBELSUS semaglutide 3 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBELSUS semaglutide 7 mg tablet blister pack.
-
Australian public assessment report (AusPar)Rybelsus (semaglutide) has been approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
-
Australian public assessment report (AusPar)AusPAR for SOGROYA (somapacitan) indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency.
-
Designation or determinationOrphan drug